Medical management of Parkinson's disease

P and T

Volumn 33, Issue 10, 2008, Pages

  Goldenberg, Marvin M ^a  

^a Marvin M Goldenberg LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; FREE RADICAL;

BRADYKINESIA; CLINICAL FEATURE; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; COST OF ILLNESS; DEMENTIA; DEPRESSION; DYSARTHRIA; DYSPHAGIA; EMOTIONALITY; ENVIRONMENTAL EXPOSURE; GENETIC ASSOCIATION; HUMAN; MORBIDITY; MUSCLE RIGIDITY; NERVE CELL DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PATHOGENESIS; PATIENT ASSESSMENT; POSITIONAL VERTIGO; POSITRON EMISSION TOMOGRAPHY; REVIEW; SKIN DISEASE; SLEEP DISORDER; SUBSTANTIA NIGRA; URINARY DYSFUNCTION;

EID: 55249089986     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998;339:1044-1053.
2. Gibb WR. Neuropathology of Parkinson's disease-related syndromes. Neurol Clin 1992;10:361-376.
3. Fearnley J, Lees A. Pathology of Parkinson's disease. In: Calne DB, ed. Neurodegenerative Diseases. Philadelphia, PA: WB Saunders; 1994:545-554.
4. Braak H, Braak E. Pathology of Alzheimer's disease. In: Calne DB, ed. Neurodegenerative Diseases. Philadelphia, PA: WB Saunders, 1994; 585-614.
5. National Parkinson Foundation. About Parkinson disease: Who gets Parkinson's disease? April 2008. Available at www.parkinson.org/netcommunity/ page.aspx?pid=225&srcid=201.
6. Albin RL. Parkinson's disease: Background, diagnosis, and initial management. Clin Geriatr Med 2006;22:735-751.
7. Bower JH, Maraganore DM, McDonnell SK, et al. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999:1214-1220.
8. LeWitt PA. Tobacco smoking, nicotine, and neuroprotection. In: Factor SA, Weiner WJ, eds. Parkinson's Disease: Diagnosis and Clinical Management. New York: Demos; 2002:519-529.
9. Hardy J, Cookson MR, Singleton A. Genes and parkinsonism. Lancet Neurol 2003;2:221-228.
10. National Institute of Neurological Disorders and Stroke. Available at: www.ninds.nih.gov/disorders/parkinsons_disease/detail_parkinsons_disease.htm. April 2008. Accessed May 3, 2008.
11. Ruane C. What is Parkinson's disease? Available at www.ezilon.com/ information/printer_15984.shtml. February 2006. Accessed May 3, 2008.
12. Aminoff MJ. Pharmacologic management of parkinsonism and other movement disorders. In: Katzung BG, ed. Basic and Clinical Pharmacology, 10th ed. New York: McGraw-Hill Lange Medical; 2007:442-451.
13. Hauser R. Long-term care of Parkinson's disease: Strategies for managing 'wearing off' symptom re-emergence and dyskinesias. Geriatrics 2006;61:14-20.
14. Alam ZI, Daniel SE, Lees AJ, et al. A generalized increase in protein carbonyls in the brain of Parkinson's but not incidental Lewy body disease. J Neurochem 1997;69:1326-1329.
15. LeWitt PA. Parkinson's disease: Etiologic considerations. In: Ahlskog JE, Adler CA. eds. Parkinson's Disease and Movement Disorders: Diagnosis and Treatment Guidelines for the Practicing Physician. New York: Humana Press; 2000:91-100.
16. Leegwater-Kim J, Waters C. Parkinsonism. In: Rakel RE, Bope ET, eds. Conn's Current Therapy. Philadelphia: WB Saunders, Elsevier; 2008:931-936.
17. Di Fonzo A, Tassorelli C, De Mari M, et al. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur J Hum Genet 2006;14:322-331.
18. Whaley NR, Uitti RJ, Dickson DW, et al. Clinical and pathologic features of families with LRRK2-associated Parkinson's disease. J Neural Transm Suppl 2006;(70):221-229.
19. Mata IF, Wedemeyer WJ, Farrer MJ, et al. LRRK2 in Parkinson's disease: Protein domains and functional insights. Trends Neurosci 2006;29(5):286-293. Electronic version, April 17, 2006.
20. Nelson MV, Berchou RC, LeWitt PA. Parkinson's disease. In: DiPiro JT, Talbert RL, Yee GC, et al., eds. Pharmacotherapy, A Physiologic Approach, 6th ed. New York: McGraw-Hill; 2005:1075-1088.
21. Jankovic J. Parkinson's disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368-376.
22. Kawahara K, Hashimoto M, Bar-On P, et al. Alpha-synuclein aggregates interfere with parkin solubility and distribution: Role in the pathogenesis of Parkinson's disease. J Biol Chem 2008;283(11):6979-6987.
23. Fahn S. Parkinson's disease and related disorders. In: Hazzard WR, Blass JP, Halter JB, et al., eds. Principles of Geriatric Medicine and Gerontology. New York: McGraw-Hill; 2003:1401-1408.
24. Ahlskog JE. Parkinson's disease: Medical and surgical treatment In: Hurtig HI, Stern MB, eds. Neurol Clin Mov Disord 2001;19(3): 579-605.
25. Michigan Parkinson foundation. Available at www.parkinsonsmi.org/facts. asp#5. Accessed September 12, 2008.
26. Hirsch ML. Cognitive changes in Parkinson's disease. American Parkinson Disease Association, 2008. Available at www.waparkinsons.org/edu_research/ articles/Cognitive_Changes.html. Accessed May 3, 2008.
27. Marsh, L. Not just a movement disorder: Cognitive changes in PD. Parkinson's Disease Foundation, Winter 2007-2008. Available at: www.pdf.org/Publications/newsletters/winter07_08/Not_Just_a_Movement.cfm. Accessed May 3, 2008.
28. Galvin JE. Cognitive change in Parkinson disease. Alzheimer Dis Assoc Disord 2006;20:302-310.
29. Standaert DG, Young AB. Treatment of central nervous system degenerative disorders. In: Hardman JG, Limbird LE, Molinoff PB et al., eds. The Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill; 1996:503-519.
30. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
31. Stalevo, prescribing information, Novartis. Available at: www.pharma.us.novartis.com/product/pi/pdf/stalevo.pdf. Accessed April 2008.
32. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one-month double blind study in parkinsonian patients with levodopa-related fluctuations. J Neurol Neurosurg Psychiatry 1996;60:36-40.
33. Frucht S, Rogers JG, Greene PE, et al. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999;52:1908-1910.
34. Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson's disease: A randomized, controlled trial. JAMA 2000;284:1931-1938.
35. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-1491.
36. Ropinirole (Requip), prescribing information. GlaxoSmithKline, October 2006. Available at: http://us.gsk.com/products/assets/us_requip.pdf. Accessed September 9, 2008.
37. Pramipexole (Mirapex), prescribing information, Boehringer Ingelheim. Available at http://bidocs.boehringer-ingelheim.com. Accessed September 25, 2008.
38. Haq IU, Lewitt PA, Fernandez HH. Apomorphine therapy in Parkinson's disease: A review. Exp Opin Pharmacother 2007;8:2799-2809.
39. Apomorphine (Apokyn), prescribing information, Vernalis. Available at: www.drugs.com/pro/apokyn.html. Accessed September 25, 2008.
40. Rotigotine Transdermal System (Neupro). Schwarz Pharma. Available at: www.schwarzpharma.com. Accessed May 5, 2008.
41. Parkinson Study Group. Entacapone improved motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:744-755. Erratum, Ann Neurol 1998;44:292.
42. Kurth MC, Adler CH, Hillarie MS, et al. Tolcapone improved motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multimember, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuate Study Group 1. Neurology 1997;48:81-87.
43. Tolcapone (Tasmar), prescribing information, Valeant Available at: www.valeant.com/fileRepository/products/PI/Tasmar_PI_Feb_2006.pdf. Accessed September 15, 2008.
44. Entacapone (Comtan), prescribing information, Novartis. Available at: www.pharma.us.novartis.com/product/pi/pdf/comtan.pdf. Accessed September 15, 2008.
45. Olanow CW. MAO-B inhibitors in Parkinson's disease. Adv Neurol 1993;60:666-671.
46. Waters CH, Sethi KD, Hauser RA, et al. Zydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study. Mov Disord 2004;19:426-432.
47. Coelho M, Ferreira J, Sampaio C. Parkinson's disease. In: Candelise L, Hughes R, Liberati A, et al., eds. Evidence-Based Neurology: Management of Neurological Disorders. Malden, MA: Blackwell Publishing; 2007.
48. Chen JJ, Swope DM. Pharmacotherapy for Parkinson's disease. Pharmacotherapy 2007;27:161S-173S.
49. deMarcaida JA, Schwid SR, White WB, et al., and the Parkinson Study Group TEMPO and PRESTO Tyramine Substudy Investigators and Coordinators. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord 2006;21:1716-1721.
50. Olanow CW, Rascol O. Early rasagiline treatment slows UPDRS decline in the ADAGIO delayed-start study. Presented at the 133rd annual meeting of the American Neurological Association, Salt Lake City, Utah, September 21-24, 2008. Available at: www.abstracts2wew.com/ana.
51. Horn JR, Hansten PD. Preventing rasagiline drug interactions. Pharmacy Times 2007;73(1):80.
52. Cogentin, adverse effects. WebMD. Available at: www.webmd.com/drugs/drug- 279-Cogentin+Inj.aspx?drugid=279&drugname=Cogentin+Inj&pagenumber=6. Accessed September 15, 2008.
53. Hallett PJ, Standaert DG. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol Ther 2004;102:155-174.
54. Amantadine (Symmetrel), prescribing information, Endo, 2003. Available at: www.endo.com/PDF/amantadine_pack_insert.pdf. Accessed September 16, 2008.
55. Cantuti-Castelvetri I, Standaert DG. Neuroprotective strategies for Parkinson's disease. Curr Neuropharm 2004;2:153-168.
56. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: The TEMPO Study. Arch Neurol 2002;59:1937-1943.
57. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-1550.
58. Storch A, Jost WH, Vieregge P, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease. Arch Neurol 2007;64(7)538-944. Electronic version, May 14, 2007.
59. Romano CJ. Levodopa and Parkinson's disease progression: Contradictory results from the ELLDOPA study. Neurologyreviews.com, 2003:11(6).